SARPODEX Trademark

Trademark Overview


On Thursday, October 6, 2016, a trademark application was filed for SARPODEX with the United States Patent and Trademark Office. The USPTO has given the SARPODEX trademark a serial number of 87195772. The federal status of this trademark filing is REGISTERED as of Tuesday, January 15, 2019. This trademark is owned by EXCIVA UG (haftungsbeschränkt). The SARPODEX trademark is filed in the Pharmaceutical Products category with the following description:

Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of inf...
sarpodex

General Information


Serial Number87195772
Word MarkSARPODEX
Filing DateThursday, October 6, 2016
Status700 - REGISTERED
Status DateTuesday, January 15, 2019
Registration Number5656270
Registration DateTuesday, January 15, 2019
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 19, 2017

Trademark Statements


Goods and ServicesMedical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the prevention of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, elixirs for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations in the form of granules and liquids for controlling and removing moss; Preparations in the form of powders for controlling and removing moss; Preparations to destroy mildew; Preparations to prevent chewing or biting by animals; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 13, 2016
Primary Code005
First Use Anywhere DateMonday, July 2, 2018
First Use In Commerce DateMonday, July 2, 2018

Trademark Owner History


Party NameEXCIVA GMBH
Party Type31 - New Owner After Registration
Legal Entity Type27 - NOT AVAILABLE
AddressVERNON HILLS 69118
DE

Party NameEXCIVA UG (haftungsbeschränkt)
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressHeidelberg 69118
DE

Party NameEXCIVA UG (haftungsbeschränkt)
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressHeidelberg 69118
DE

Party NameEXCIVA UG (haftungsbeschränkt)
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressHeidelberg 69118
DE

Trademark Events


Event DateEvent Description
Monday, January 15, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Thursday, June 11, 2020REVIEW OF CORRESPONDENCE COMPLETE - INFORMATION MADE OF RECORD
Wednesday, May 13, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sunday, March 8, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sunday, March 8, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, March 8, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Sunday, March 8, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sunday, March 8, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sunday, March 8, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 7, 2019AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, January 15, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, December 11, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Saturday, December 8, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Saturday, December 1, 2018STATEMENT OF USE PROCESSING COMPLETE
Wednesday, November 14, 2018USE AMENDMENT FILED
Saturday, December 1, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, November 14, 2018TEAS STATEMENT OF USE RECEIVED
Wednesday, May 16, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 14, 2018SOU EXTENSION 1 GRANTED
Monday, May 14, 2018SOU EXTENSION 1 FILED
Monday, May 14, 2018SOU TEAS EXTENSION RECEIVED
Tuesday, November 14, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, September 27, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 26, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 19, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 19, 2017PUBLISHED FOR OPPOSITION
Wednesday, August 30, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, August 12, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 24, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 24, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 18, 2017ASSIGNED TO LIE
Sunday, June 11, 2017TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, May 1, 2017NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, May 1, 2017FINAL REFUSAL E-MAILED
Monday, May 1, 2017FINAL REFUSAL WRITTEN
Thursday, April 27, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 27, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 27, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 16, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 16, 2017NON-FINAL ACTION E-MAILED
Monday, January 16, 2017NON-FINAL ACTION WRITTEN
Friday, January 13, 2017ASSIGNED TO EXAMINER
Monday, October 17, 2016TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Monday, October 17, 2016TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, October 13, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 10, 2016NEW APPLICATION ENTERED